Research programme: biosimilars - mAbxience

Drug Profile

Research programme: biosimilars - mAbxience

Alternative Names: Adnx01; Adnx02; Adnx03; Adnx04; mAbx03; mAbx04; mAbx05; mAbx06; mAbx07; mAbx08; mAbx09

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator mAbxience
  • Class Colony-stimulating factors; Hormones; Interferons; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antigen modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)
  • 31 Jul 2013 Research programme: biosimilars - mAbxience is available for licensing as of 31 Jul 2013. http://www.mabxience.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top